BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

...a relatively selective adrenergic receptor α 2 (ADRA2) agonist, combined with loteprednol etabonate, a corticosteroid. OCU300...
BioCentury | Feb 22, 2016
Company News

University of Illinois at Chicago, Ocugen deal

...The university granted Ocugen exclusive, worldwide rights to develop and commercialize OCU300 . The repurposed undisclosed...
...analysis of an exploratory observational study in ocular graft-versus-host disease (GvHD). Ocugen plans to develop OCU300...
...or from previously approved products. In 2017, Ocugen plans to start Phase III trials of OCU300...
Items per page:
1 - 2 of 2